Peptide Schedule
Pramlintide (Symlin)37 residuesKCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTYEach bubble = one amino acid. Size = residue mass. Color = chemical class.Pramlintide (Symlin) Dosage Calculator
Pramlintide (brand name Symlin) is an FDA-approved synthetic analog of human amylin, a 37-amino acid hormone co-secreted with insulin by pancreatic beta cells after meals.
15mcg · 3x Daily
Summary: Add 0mL BAC water to your 1mg vial. Draw to < 0.1 units on a U-100 syringe for a 15mcg dose. This vial will last 0 doses.
Cycle Planner
Pramlintide (Symlin) Pharmacokinetics
Pharmacokinetics — Active Dose Over Time
t½ = ~48 minutesDisclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Pramlintide (Symlin) Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 15mcg | 3x Daily |
| Moderate | 60mcg | 2x Daily |
| Aggressive | 120mcg | 3x Daily |
Note: FDA-approved amylin analog (brand: Symlin). Injected subcutaneously before major meals. Type 1: titrate 15 mcg to 60 mcg. Type 2: titrate 60 mcg to 120 mcg. Always used as adjunct to mealtime insulin — never as a standalone. Reduce insulin dose by 50% when starting to prevent hypoglycemia.
About Pramlintide (Symlin)
Pramlintide (brand name Symlin) is an FDA-approved synthetic analog of human amylin, a 37-amino acid hormone co-secreted with insulin by pancreatic beta cells after meals. In type 1 diabetes, amylin production is essentially absent; in type 2 diabetes, it is significantly impaired. Pramlintide replaces this missing hormone. Approved in March 2005, pramlintide is the only amylin analog on the market. It works through three mechanisms that insulin cannot address: it slows gastric emptying so glucose enters the bloodstream more gradually, it suppresses inappropriate postprandial glucagon secretion from alpha cells, and it promotes satiety through central receptors in the area postrema. The net effect is significantly lower post-meal glucose spikes — something that even optimized insulin regimens struggle to achieve alone. In clinical trials, adding pramlintide to insulin therapy reduced HbA1c by 0.2-0.6% and postprandial glucose by 3.4-5 mmol/L. Patients also lost 0.5-1.6 kg of body weight, which is notable because insulin therapy typically causes weight gain. The weight loss effect, while modest, comes from reduced food intake driven by increased satiety signaling. Pramlintide carries a black box warning for severe hypoglycemia, particularly in type 1 diabetes patients. This risk is highest during the first 4 weeks and is managed by cutting the mealtime insulin dose by 50% when initiating pramlintide. It requires three daily injections before major meals, which limits adherence for some patients. Next-generation amylin analogs like cagrilintide aim to solve this with weekly dosing.